enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Mephentermine - Wikipedia

   en.wikipedia.org/wiki/Mephentermine

   Mephentermine, sold under the brand name Wyamine among others, is a sympathomimetic medication which was previously used in the treatment of low blood pressure but is mostly no longer marketed. [6] [5] [4] [7] [8] It is used by injection into a vein or muscle, by inhalation, and by mouth. [4] [5]

3. Phentermine - Wikipedia

   en.wikipedia.org/wiki/Phentermine

   In accordance with its lack of serotonin release and serotonin 5-HT 2B receptor agonism, phentermine appears to show no risk of primary pulmonary hypertension (PPH) or valvular heart disease (VHD) in humans. [32] [10] [27] Phentermine has been found to be active as an agonist of the rat and human trace amine-associated receptor 1 (TAAR1).

4. Anti-obesity medication - Wikipedia

   en.wikipedia.org/wiki/Anti-obesity_medication

   Phentermine is a substituted amphetamine and topiramate has an unknown mechanism of action Approved for weight management (short-term) by the FDA but not the European Medicines Agency [ 54 ] 10% [ 55 ] or 8.25 kilograms (18.2 lb) [ 56 ]

5. Where To Get Cheap Flu Shots - AOL

   www.aol.com/where-cheap-flu-shots-walmart...

   Safeway: $30. With a discount card, Safeway offers quadrivalent flu shots for about $30. The chain is advertising a coupon for 10% off your next grocery purchase up to $200 with any immunization ...

6. FDA approves new pain medication as an alternative to opioids ...

   www.aol.com/fda-approves-pain-medication...

   For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

7. Phentermine/topiramate - Wikipedia

   en.wikipedia.org/wiki/Phentermine/topiramate

   Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.